Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 02325 YUNKANG GROUP > Detailed Quotes

02325 YUNKANG GROUP

Watchlist
15.740
-0.060-0.38%
Closed  02/08 16:08 CCT
High
15.900
Open
15.740
Turnover
3.10M
Low
15.700
Pre Close
15.800
Volume
196.00K
Market Cap
9.78B
P/E(TTM)
18.22
52wk High
19.092
Shares
621.25M
P/E(Static)
20.99
52wk Low
6.512
Float Cap
9.78B
Bid/Ask %
50.00%
Historical High
19.092
Shs Float
621.25M
Volume Ratio
0.11
Historical Low
6.512
Dividend TTM
0.088
Div Yield TTM
--
P/B
3.40
Dividend LFY
0.56%
Div Yield LFY
--
Turnover Ratio
0.03%
Amplitude
1.27%
Avg Price
15.804
Lot Size
500
Float Cap
9.78B
Bid/Ask %
50.00%
Historical High
19.092
Shs Float
621.25M
Volume Ratio
0.11
Historical Low
6.512
Dividend TTM
0.088
P/B
3.40
Dividend LFY
0.56%
Turnover Ratio
0.03%
Amplitude
1.27%
Avg Price
15.804
Lot Size
500
Price Forecast

News

Comment

Company Overview More
Yunkang Group is a medical operation service provider in China. As early as 2008, Yunkang began providing standardized medical diagnosis services to medical institutions at all levels. Through the use of its professional diagnostic capabilities and medical consortium service network covering the whole country, Yunkang has gradually developed into a leading platform for medical operation services. Its testing programs have continued to increase, and it has carried out more than 2,000 testing programs and more than 50 million diagnostic tests in 2021. As far as revenue in 2020 is concerned, as one of the top five companies in the Chinese medical operation service market, we have three major business lines, covering diagnostic testing services for medical consortia, diagnostic outsourcing services, and diagnostic testing services for non-medical institution customers. As of April 25, 2022, from the establishment of six operating modules and seven major technology platforms to six independent clinical laboratories covering key provinces and cities across the country, Yunkang has the largest number of first-class independent laboratories accredited by ISO15189 and CAP in the country, as well as more than 1,450 medical technicians. We have provided comprehensive, high-quality clinical diagnosis services to partner hospitals over a long period of time with accurate clinical diagnosis capabilities. At the same time, Yunkang is also a leading medical consortium diagnostic service provider in China, providing a full range of medical and health services covering medical consortium diagnosis and diagnosis outsourcing. Yunkang provides diagnostic testing services to partner hospitals within the Chinese Medical Federation and assists them in improving their clinical diagnosis capabilities through on-site diagnostic centers. Up to now, Yunkang has successfully provided professional services to more than 700 medical institutions from more than 300 medical consortia across the country. As of December 31, 2021, the hospitals we have cooperated with are distributed in 31 provinces and cities in China, most of which are located in Guangdong Province, where our headquarters is located. Over the past ten years, Yunkang has achieved sustainable growth through professional medical diagnostic services, strong standardization capabilities, innovative diagnostic and testing service business models for medical consortia, a large loyal customer base, and a visionary and experienced management team. Technology Yunkang, service health! Yunkang will continue to work to create a better and healthy life for all residents.
CEO: Yong Zhang
Market: Hong Kong motherboard
Listing Date: 05/18/2022
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist